Promega and SignalChem Pharma said that the solution is a combination of an expanding series of Kinase Enzyme Systems and Promega’s new, bioluminescent ADP-Glo Kinase Assay, which is expected to provide all of the necessary tools and give drug screeners the ease to profile inhibitors against the human kinome for off-target effects.
Promega claimed that its ADP-Glo Kinase Assay is as sensitive as radiometric kinase assays and is used to optimise and QC the Kinase Enzyme Systems
Each Kinase System is made up of a protein kinase enzyme, cognate kinase substrate and enzyme buffer.
Jasbinder Sanghera, president and CSO of SignalChem Pharmaceuticals, said: “This partnering of SignalChem’s kinase reagents with the Promega ADP-Glo detection assay for kinases is an ideal fit. Now researchers can obtain all the necessary components to test protein kinase inhibition from a single source while still obtaining the level of sensitivity obtained with traditional radiometric assays.”